MREO — Mereo BioPharma Group plc
Price · 2024-08-26 → 2026-08-21
499 daily closes shownAnonymous view is capped at two years of history. A free account extends it to five, and Pro opens the whole archive back to 2019-04-24.
Performance
Technicals
Others in Healthcare
Measured signals that fired on MREO
| date | signal | measured base rate |
|---|---|---|
| 2026-04-09 | Equal lows taken out structure | -0.64% over 21 days · t = -4.75 · n = 55,661 statistically distinguishable from its control group |
Excess return against a matched control group, on a point-in-time universe that includes delisted companies. Most families do not survive that. How the measurement works →
Insider transactions (Form 4)
| date | insider | what | shares | price | value |
|---|---|---|---|---|---|
| 2024-09-13 | Hughes-Wilson Alexandra See Remarks | Open-market sale | 84.0K | 4.22 | 354.5K |
| 2024-09-13 | Scots-Knight Denise Chief Executive Officer | Open-market sale | 60.0K | 4.22 | 253.4K |
| 2024-09-13 | Sermon Charles General Counsel | Open-market sale | 20.9K | 4.22 | 88.4K |
| 2024-09-13 | Fox Christine Ann Chief Financial Officer | Open-market sale | 19.2K | 4.22 | 80.8K |
| 2024-09-13 | Hughes-Wilson Alexandra See Remarks | Open-market sale | 16.3K | 4.22 | 68.8K |
| 2024-09-13 | Lewicki John A. Chief Scientific Officer | Open-market sale | 10.9K | 4.22 | 46.2K |
| 2024-09-12 | Hughes-Wilson Alexandra See Remarks | Open-market sale | 40.0K | 4.47 | 178.9K |
| 2024-09-12 | Scots-Knight Denise Chief Executive Officer | Open-market sale | 28.6K | 4.47 | 127.9K |
| 2024-09-12 | Sermon Charles General Counsel | Open-market sale | 10.0K | 4.47 | 44.6K |
| 2024-09-12 | Fox Christine Ann Chief Financial Officer | Open-market sale | 9.1K | 4.47 | 40.8K |
Open-market purchases (code P) are the informative ones. Grants, option exercises and tax withholding are compensation mechanics, not decisions. How to read a Form 4 →
Largest institutional holders
| manager | value | shares |
|---|---|---|
| Rubric Capital Management LP | 5.1M | 15.3M |
| EcoR1 Capital, LLC | 4.4M | 13.4M |
| 683 Capital Management, LLC | 4.0M | 12.0M |
| BANK OF AMERICA CORP /DE/ | 2.7M | 8.2M |
| Defilade Capital Management, L.P. | 2.5M | 7.6M |
| Newtyn Management, LLC | 2.3M | 7.1M |
| MILLENNIUM MANAGEMENT LLC | 1.2M | 3.6M |
| Tejara Capital Ltd | 672.4K | 2.0M |
| UBS Group AG | 491.7K | 1.5M |
| Wealthspire Advisors, LLC | 262.7K | 796.0K |
13F positions as of 2026-03-31, filed up to 45 days after quarter end. Long-only US equity — shorts and derivatives never appear. What 13F does and does not show →
Short selling
This is off-exchange short volume, not short interest: it is flow, not position, and 40–50% is normal because market makers short to fill your buy. Why that number misleads →
Ask the AI about MREO
The assistant reads every block on this page — price history, filings, insider transactions, institutional positions, short volume, macro and the measured base rates — and says what it implies, quoting the number behind each claim and declaring what it does not have.
Everything on this page is live in the terminal.
Charts, filings, insider flow and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →